Document is current
Any future updates will be listed below
-
Authors
Lieschke, Franziska
Marggrander, Daniel T.
Rauch, Maximilian
Schaefer, Jan Hendrik
Bohmann, Ferdinand O.
Foerch, Christian
Grefkes, Christian
Kohlhase, Konstantin https://orcid.org/0000-0002-1088-9558
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 7 November 2025
First Online: 3 December 2025
Declarations
:
: Prof. Foerch holds the patent for using GFAP for identification of intracerebral hemorrhage (US20150247867) and further reports speaker honoraria and honoraria for participating in advisory boards from Abbott, Alexion, Bristol Myers Squibb, Novartis, Teva, Merck, Sanofi Genzyme, and Roche. The university hospital Frankfurt received a research grant from Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945) for the development and validation of brain-specific biomarkers in urine. K. Kohlhase and C. Foerch were responsible for the financial distribution of the research grant. However, the measurements presented in this manuscript were not directly supported or funded by this research grant and therefore had no influence on the study design, data acquisition, data analysis, interpretation of results, or manuscript preparation. Dr. Bohmann reports speaker honoraria from Laerdal, AstraZeneca, Bristol-Myers-Squibb, Pfizer, Medtronic and grants and personal fees from Alexion, AstraZeneca, Stryker Neurovascular, Boehringer Ingelheim. Dr. Schaefer reports travel reimbursements by Bayer AG outside of the submitted work. The other authors report no conflicts.
